Cereno Scientific completes preclinical safety program for innovative drug candidate CS014 targeting thrombosis prevention and reaches a major preparatory milestone towards the Phase I study
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that the preclinical safety program for drug candidate CS014 has successfully been completed. The safety documentation is a key component needed to apply for permission from regulatory authorities to start a first-in-human Phase I study. The Phase I study will be conducted in Sweden in partnership with the contract research organization (CRO) Clinical Trial Consultants (CTC) and is planned to start during the first half of 2024.“This is a